Additional file 9: Table S9. Summary of univariate Cox proportional hazard analysis of the previously identified CpGs. Column variables represent Name; chr; chromosome number, pos; position, CpG name, relation_to_Island; where is CpG located in relationship to island, UCSC RefGene Name; UCSC gene name, UCSC RefGene Accession; UCSC gene accession, UCSC RefGene Group; where in respect to gene is CpG located, Beta; estimated coefficient beta from the model, StandardError; standard error, Z; z-score, LRT; likelihood ratio...

Abstract Background COVID-19 infections could be complicated by acute respiratory distress syndrome (ARDS), increasing mortality risk. We sought to assess the methylome of peripheral blood mononuclear cells in COVID-19 with ARDS. Methods We recruited 100 COVID-19 patients with ARDS under mechanical ventilation and 33 non-COVID-19 controls between April and July 2020. COVID-19 patients were followed at four time points for 60 days. DNA methylation and immune cell populations were measured at each time point. A...

Additional file 2: Table S2. Summary of different models tested for estimating differences between controls and COVID-19 patients for immune cell proportions. Adjusted R2, residual standard error (sigma), AIC, and p.value for each tested model for each cell type are shown. The following models were tested, mod1; Age and ethnicity as covariates, mod2; age as a covariate, mod3; ethnicity as a covariate, mod4; no covariates.

Abstract Background Advances in our understanding of the tumor microenvironment have radically changed the cancer field, highlighting the emerging need for biomarkers of an active, favorable tumor immune phenotype to aid treatment stratification and clinical prognostication. Numerous immune-related gene signatures have been defined; however, their prognostic value is often limited to one or few cancer types. Moreover, the area of non-coding RNA as biomarkers remains largely unexplored although their number and biological roles are rapidly...

Additional file 9: Correlation of 3 ir-lncRNA signature with immune subpopulations across tumor types. Pearson correlation heatmap between immune cell subpopulation enrichment scores and 3 ir-lncRNA scores.

Additional file 2: Differentially expressed lncRNAs in TCGA-BRCA

Additional file 2: Differentially expressed lncRNAs in TCGA-BRCA

Additional file 4: Canonical pathways, diseases and functions associated with the 127 proxy protein-coding genes.

Additional file 1.

Abstract Background This study aimed to enhance the cultural adaptation and training on administering the Arabic versions of the Calgary Depression Scale in Schizophrenia (CDSS) and The International Scale for Suicidal Thinking (ISST) to Arab schizophrenia patients in Doha, Qatar. Methods We applied the qualitative thematic analysis of the focus group discussions with clinical research coordinators (CRCs). Five CRCs met with the principal investigator for two sessions; we transcribed the conversations and analyzed the content....

Additional file 1. Appendix 1: Hospitals Covered by Hamad Medical Corporation (HMC) in Qatar. Appendix 2: Antibiotic Susceptibility and D Tests for 196 invasive GBS bacteraemia isolates.

Additional file 10: Table S10. Description of the eight genes that are predictors of mortality. Data were collected from Gene Ontology (GO) to identify the functional annotation of each gene and recently published COVID-19 related articles to highlight the role of each gene in relation to COVID-19.

Additional file 4: Table S4. Summary of differentially methylated pathways detected between COVID-19 patients and controls based on CpG sites.

Additional file 2: Table S2. Summary of different models tested for estimating differences between controls and COVID-19 patients for immune cell proportions. Adjusted R2, residual standard error (sigma), AIC, and p.value for each tested model for each cell type are shown. The following models were tested, mod1; Age and ethnicity as covariates, mod2; age as a covariate, mod3; ethnicity as a covariate, mod4; no covariates.

Additional file 3: Table S3. Summary of identified differentially methylated CpGs between COVID-19 patients and controls. A. All significant CpGs B. Variable description from Table S2A. C. Significant CpGs from genes previously described as COVID-19 important [1]. D. Functional annotation of genes from Supplemental table 3C.

Additional file 6: Table S6. Analysis of dead and recovered+A3 COVID-19 patients for immune cell proportions. A. Summary of different models tested for immune cell proportions. Adjusted R2, residual standard error (sigma), AIC, and p-value for each tested model for each cell type are shown. The following models were tested, mod1; Age + MV days + Gender + ICU LoS + ECMO + Nosocomial infections, mod2; Age + Gender + ICU LoS + ECMO +...

Additional file 8: Table S8. Description of 27 genes from 49 differentially methylated CpGs between survived and dead patients over four time points. A summarized description of the 27 genes obtained from Supplementary Table 7B, collected from Gene Ontology (GO) to identify the functional annotation of each gene and recently published COVID-19-related articles to highlight the role of each gene in relation to COVID-19.

Additional file 8: Table S8. Description of 27 genes from 49 differentially methylated CpGs between survived and dead patients over four time points. A summarized description of the 27 genes obtained from Supplementary Table 7B, collected from Gene Ontology (GO) to identify the functional annotation of each gene and recently published COVID-19-related articles to highlight the role of each gene in relation to COVID-19.

Free-floating right-heart thrombus (FFRHT) in the context of a pulmonary embolism (PE) is a rare but serious encounter with no guidelines addressing its management. We performed a systematic review and meta-analysis addressing prevalence, clinical behavior, and outcomes of FFRHT associated with PE. Among the included 397 patients with FFRHT and PE, dyspnea was the main presenting symptom (73.3%). Obstructive shock was documented in 48.9% of cases. Treatment with thrombolytic therapy, surgical thrombectomy, and percutaneous thrombectomy...

Additional file 2. Questionnaire.